Sponsor:
M.D. Anderson Cancer Center
Code:
NCT03214510
Conditions
Liver and Intrahepatic Bile Duct Disorder
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bupivacaine
Fentanyl
Hydromorphone Hydrochloride
Implanted Medical Device
Implanted Medical Device
Brief summary:
Conditions
Liver and Intrahepatic Bile Duct Disorder
Study ID
NCT03214510
Start date
Oct 4, 2017
Status verified date
Nov, 2026
Completion date
Jul 31, 2027
Anticipated
Primary completion date
Jul 31, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
108 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Supportive Care
Arms
experimental: Arm I (TAE)
experimental: Arm II (TAP)
Interventions
Bupivacaine
Fentanyl
Hydromorphone Hydrochloride
Implanted Medical Device
Implanted Medical Device
Liposomal Bupivacaine
Questionnaire
Primary outcome measure
Locations
M D Anderson Cancer Center
Recruiting
Houston, Texas, United States, 77030
Contacts
Principal Investigator:
Timothy E. Newhook
Sponsor
M.D. Anderson Cancer Center
Last update posted
Nov 17, 2026
Last verified
Nov, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.